Company Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
0.9131 ^USD	+1.68%		+1.47%	-3.88%

Dec. 19	IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	CI
Dec. 10	Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	CI

Business description: Imunon, Inc.

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Number of employees: 33

Sales by Activity: Imunon, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Oncology Drug Development	500K	500K	500K	500K	-

See all business segments

Geographical breakdown of sales: Imunon, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
United States	500K	500K	500K	500K	-

See all geographic segments

Managers: Imunon, Inc.

Director	Title	Age	Since
Stacy Lindborg CEO	Chief Executive Officer	54	2024-05-12
David Gaiero DFI	Director of Finance/CFO	46	2024-05-31
Sebastien Hazard CTO	Chief Tech/Sci/R&D Officer	54	2023-12-10
Khursheed Anwer CTO	Chief Tech/Sci/R&D Officer	65	2014-06-19
Kimberly Bragg AUD	Comptroller/Controller/Auditor	-	-

See IMUNON, INC. governance

Members of the board: Imunon, Inc.

Manager	Title	Age	Since
Michael Tardugno CHM	Chairman	74	2014-10-06
Frederick Fritz BRD	Director/Board Member	74	2011-07-07
Donald Braun BRD	Director/Board Member	75	2015-12-14
Stacy Lindborg BRD	Director/Board Member	54	2021-06-03
Christine Pellizzari BRD	Director/Board Member	57	2021-06-07
James Dentzer BRD	Director/Board Member	58	2022-09-02

Composition of the Board of Directors

Shareholders: Imunon, Inc.

Name	Equities	%	Valuation
Ayrton Capital LLC 7.272 %	1,054,438	7.272 %	1 M $
Sabby Management LLC 4.194 %	608,203	4.194 %	577 793 $
Michael Tardugno 2.437 %	353,346	2.437 %	335 679 $
Stacy Lindborg 1.822 %	264,166	1.822 %	250 958 $
Geode Capital Management LLC 0.8685 %	125,935	0.8685 %	119 638 $

List of IMUNON, INC. shareholders

Company details: Imunon, Inc.

Imunon, Inc.

997 Lenox Drive Suite 100

08648, Lawrenceville

+609 896 9100

http://imunon.com

Bio Therapeutic Drugs

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
IMUNON, INC.	+1.68%	+1.47%	+60.19%	-85.92%	13.24M
VERTEX PHARMACEUTICALS INCORPORATED	+1.21%	+3.04%	-2.99%	+82.81%	109B
REGENERON PHARMACEUTICALS, INC.	-1.68%	-2.20%	-26.98%	+10.27%	73.33B
ARGENX SE	-0.34%	-1.73%	+89.79%	+149.65%	39.62B
BIONTECH SE	-0.74%	-8.89%	+13.96%	-30.76%	26.83B
BEIGENE, LTD.	+2.31%	+18.88%	+31.48%	-11.30%	22.39B
WUXI APPTEC CO., LTD.	+5.72%	+5.00%	-25.18%	-49.97%	20.68B
NEUROCRINE BIOSCIENCES, INC.	+0.94%	+1.67%	+4.29%	+96.70%	14.5B
SUMMIT THERAPEUTICS INC.	+4.62%	+6.61%	+427.15%	+749.55%	14.03B
GENMAB A/S	+0.03%	-3.55%	-23.38%	-34.85%	13.23B
Average	+1.37%	+1.54%	+54.83%	+87.62%	33.33B
Weighted average by Cap.	+0.67%	+1.17%	+22.68%	+75.09%